Frequent retention of heterozygosity for point mutations in p53 and Ikaros in N-ethyl-N-nitrosourea-induced mouse thymic lymphomas

Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis

Volumn 572, Issue 1-2, 2005, Pages 132-141

  Kakinuma, Shizuko ^a   Nishimura, Mayumi ^a   Kubo, Ayumi ^a   Nagai, Jun Ya ^a   Amasaki, Yoshiko ^a   Majima, Hideyuki J ^b   Sado, Toshihiko ^a   Shimada, Yoshiya ^a  

^a NATIONAL INSTITUTE OF RADIOLOGICAL SCIENCES   (Japan)

^b KAGOSHIMA UNIVERSITY   (Japan)

Author keywords

ENU; Heterozygous mutation; Ikaros; p53

Indexed keywords

ANIMAL CELL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DISEASE ASSOCIATION; GENE FREQUENCY; GENE LOCATION; GENE MAPPING; GENE MUTATION; HETEROZYGOSITY; LYMPHOMA; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; RNA SPLICING; SEQUENCE ANALYSIS; THYMUS; TUMOR SUPPRESSOR GENE; WILD TYPE;

EID: 15544384575     PISSN: 00275107     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.mrfmmm.2005.01.010     Document Type: Article

References (45)

1. A.G. Knudson Jr. Mutation and cancer: statistical study of retinoblastoma Proc. Natl. Acad. Sci. U.S.A. 68 1971 820 823
2. A.G. Knudson Antioncogenes and human cancer Proc. Natl. Acad. Sci. U.S.A. 90 1993 10914 10921
3. J.M. Nigro, S.J. Baker, A.C. Preisinger, J.M. Jessup, R. Hostetter, K. Cleary, S.H. Bigner, N. Davidson, S. Baylin, and P. Devilee Mutations in the p53 gene occur in diverse human tumour types Nature 342 1989 705 708
4. R. Mazars, L. Spinardi, M. BenCheikh, J. Simony-Lafontaine, P. Jeanteur, and C. Theillet p53 mutations occur in aggressive breast cancer Cancer Res. 52 1992 3918 3923
5. P. Wang, M. Reed, Y. Wang, G. Mayr, J.E. Stenger, M.E. Anderson, J.F. Schwedes, and P. Tegtmeyer p53 domains: structure, oligomerization, and transformation Mol. Cell. Biol. 14 1994 5182 5191
6. K.G. McLure, and P.W. Lee How p53 binds DNA as a tetramer EMBO J. 17 1998 3342 3350
7. L. Sun, N. Heerema, L. Crotty, X. Wu, C. Navara, A. Vassilev, M. Sensel, G.H. Reaman, and F.M. Uckun Expression of dominant-negative and mutant isoforms of the antileukemic transcription factor Ikaros in infant acute lymphoblastic leukemia Proc. Natl. Acad. Sci. U.S.A. 96 1999 680 685
8. L. Sun, M.L. Crotty, M. Sensel, H. Sather, C. Navara, J. Nachman, P.G. Steinherz, P.S. Gaynon, N. Seibel, C. Mao, A. Vassilev, G.H. Reaman, and F.M. Uckun Expression of dominant-negative Ikaros isoforms in T-cell acute lymphoblastic leukemia Clin. Cancer Res. 5 1999 2112 2120
9. L. Sun, P.A. Goodman, C.M. Wood, M.L. Crotty, M. Sensel, H. Sather, C. Navara, J. Nachman, P.G. Steinherz, P.S. Gaynon, N. Seibel, A. Vassilev, B.D. Juran, G.H. Reaman, and F.M. Uckun Expression of aberrantly spliced oncogenic Ikaros isoforms in childhood acute lymphoblastic leukemia J. Clin. Oncol. 17 1999 3753 3766 see comments
10. H. Nakayama, F. Ishimaru, N. Avitahl, N. Sezaki, N. Fujii, K. Nakase, Y. Ninomiya, A. Harashima, J. Minowada, J. Tsuchiyama, K. Imajoh, T. Tsubota, S. Fukuda, T. Sezaki, K. Kojima, M. Hara, H. Takimoto, S. Yorimitsu, I. Takahashi, A. Miyata, S. Taniguchi, Y. Tokunaga, H. Gondo, Y. Niho, and M. Harada Decreases in Ikaros activity correlate with blast crisis in patients with chronic myelogenous leukemia Cancer Res. 59 1999 3931 3934
11. S. Winandy, P. Wu, and K. Georgopoulos A dominant mutation in the Ikaros gene leads to rapid development of leukemia and lymphoma Cell 83 1995 289 299
12. L. Sun, A. Liu, and K. Georgopoulos Zinc finger-mediated protein interactions modulate Ikaros activity, a molecular control of lymphocyte development EMBO J. 15 1996 5358 5369
13. B. Morgan, L. Sun, N. Avitahl, K. Andrikopoulos, T. Ikeda, E. Gonzales, P. Wu, S. Neben, and K. Georgopoulos Aiolos, a lymphoid restricted transcription factor that interacts with Ikaros to regulate lymphocyte differentiation EMBO J. 16 1997 2004 2013
14. Y. Shimada, M. Nishimura, S. Kakinuma, M. Okumoto, T. Shiroishi, K.H. Clifton, and S. Wakana Radiation-associated loss of heterozygosity at the Znfn1a1 (Ikaros) locus on chromosome 11 in murine thymic lymphomas Radiat. Res. 154 2000 293 300
15. S. Kakinuma, M. Nishimura, S. Sasanuma, K. Mita, G. Suzuki, Y. Katsura, T. Sado, and Y. Shimada Spectrum of Znfn1a1 (Ikaros) inactivation and its association with loss of heterozygosity in radiogenic T-cell lymphomas in susceptible B6C3F1 mice Radiat. Res. 157 2002 331 340
16. P. Lopez-Nieva, J. Santos, and J. Fernandez-Piqueras Defective expression of Notch1 and Notch2 in connection to alterations of c-Myc and Ikaros in gamma-radiation-induced mouse thymic lymphomas Carcinogenesis 25 2004 1299 1304
17. H. Okano, Y. Saito, T. Miyazawa, T. Shinbo, D. Chou, S. Kosugi, Y. Takahashi, S. Odani, O. Niwa, and R. Kominami Homozygous deletions and point mutations of the Ikaros gene in gamma-ray-induced mouse thymic lymphomas Oncogene 18 1999 6677 6683
18. T. Shibuya, and K. Morimoto A review of the genotoxicity of 1-ethyl-1-nitrosourea Mutat. Res. 297 1993 3 38
19. M.C. Poirier, R.M. Santella, and A. Weston Carcinogen macromolecular adducts and their measurement Carcinogenesis 21 2000 353 359
20. E.W. Newcomb, J.J. Steinberg, and A. Pellicer ras oncogenes and phenotypic staging in N-methylnitrosourea- and gamma-irradiation-induced thymic lymphomas in C57BL/6J mice Cancer Res. 48 1988 5514 5521
21. Y. Shimada, M. Nishimura, S. Kakinuma, T. Ogiu, H. Fujimoto, A. Kubo, J. Nagai, K. Kobayash, K. Tano, S. Yoshinaga, and K.K. Bhakat Genetic susceptibility to thymic lymphomas and K-ras gene mutation in mice after exposure to X-rays and N-ethyl-N-nitrosourea Int. J. Radiat. Biol. 79 2003 423 430
22. E. Romach, J. Moore, S. Rummel, and E. Richie Influence of sex and carcinogen treatment protocol on tumor latency and frequency of K-ras mutations in N-methyl-N-nitrosourea-induced lymphomas Carcinogenesis 15 1994 2275 2280
23. I.P. Perez de Castro, M. Malumbres, J. Santos, A. Pellicer, and J. Fernandez-Piqueras Cooperative alterations of Rb pathway regulators in mouse primary T cell lymphomas Carcinogenesis 20 1999 1675 1682
24. S.W. Wijnhoven, P.P. Van Sloun, H.J. Kool, G. Weeda, R. Slater, P.H. Lohman, A.A. van Zeeland, and H. Vrieling Carcinogen-induced loss of heterozygosity at the Aprt locus in somatic cells of the mouse Proc. Natl. Acad. Sci. U.S.A. 95 1998 13759 13764
25. S.W. Wijnhoven, H.J. Kool, C.M. van Teijlingen, A.A. van Zeeland, and H. Vrieling Loss of heterozygosity in somatic cells of the mouse. An important step in cancer initiation Mutat. Res. 473 2001 23 36
26. M. Nishimura, S. Kakinuma, S. Wakana, A. Mukaigawara, K. Mita, T. Sado, T. Ogiu, and Y. Shimada Reduced sensitivity to and ras mutation spectrum of N-ethyl-N-nitrosourea-induced thymic lymphomas in adult C.B-17 scid mice Mutat. Res. 486 2001 275 283
27. M. Nishimura, S. Wakana, S. Kakinuma, K. Mita, H. Ishii, S. Kobayashi, T. Ogiu, T. Sado, and Y. Shimada Low frequency of Ras gene mutation in spontaneous and gamma-ray-induced thymic lymphomas of scid mice Radiat. Res. 151 1999 142 149
28. Y. Shimada, M. Nishimura, S. Kakinuma, T. Takeuchi, T. Ogiu, G. Suzuki, Y. Nakata, S. Sasanuma, K. Mita, and T. Sado Characteristic association between K-ras gene mutation with loss of heterozygosity in X-ray-induced thymic lymphomas of the B6C3F1 mouse Int. J. Radiat. Biol. 77 2001 465 473
29. A. Karlsson, P. Soderkvist, and S.M. Zhuang Point mutations and deletions in the znfn1a1/Ikaros gene in chemically induced murine lymphomas Cancer Res. 62 2002 2650 2653
30. K. Georgopoulos Transcription factors required for lymphoid lineage commitment Curr. Opin. Immunol. 9 1997 222 227
31. B.S. Cobb, S. Morales-Alcelay, G. Kleiger, K.E. Brown, A.G. Fisher, and S.T. Smale Targeting of Ikaros to pericentromeric heterochromatin by direct DNA binding Genes Dev. 14 2000 2146 2160
32. A.M. Davidoff, P.A. Humphrey, J.D. Iglehart, and J.R. Marks Genetic basis for p53 overexpression in human breast cancer Proc. Natl. Acad. Sci. U.S.A. 88 1991 5006 5010
33. O. Brathwaite, W. Bayona, and E.W. Newcomb p53 mutations in C57BL/6J murine thymic lymphomas induced by gamma-irradiation and N-methylnitrosourea Cancer Res. 52 1992 3791 3795
34. A. Willis, E.J. Jung, T. Wakefield, and X. Chen Mutant p53 exerts a dominant negative effect by preventing wild-type p53 from binding to the promoter of its target genes Oncogene 23 2004 2330 2338
35. G. Liu, T.J. McDonnell, R. Montes de Oca Luna, M. Kapoor, B. Mims, A.K. El-Naggar, and G. Lozano High metastatic potential in mice inheriting a targeted p53 missense mutation Proc. Natl. Acad. Sci. U.S.A. 97 2000 4174 4179
36. A. de Vries, E.R. Flores, B. Miranda, H.M. Hsieh, C.T. van Oostrom, J. Sage, and T. Jacks Targeted point mutations of p53 lead to dominant-negative inhibition of wild-type p53 function Proc. Natl. Acad. Sci. U.S.A. 99 2002 2948 2953
37. P. Papathanasiou, A.C. Perkins, B.S. Cobb, R. Ferrini, R. Sridharan, G.F. Hoyne, K.A. Nelms, S.T. Smale, and C.C. Goodnow Widespread failure of hematolymphoid differentiation caused by a recessive niche-filling allele of the Ikaros transcription factor Immunity 19 2003 131 144
38. A.J. Paige Redefining tumour suppressor genes: exceptions to the two-hit hypothesis Cell Mol. Life Sci. 60 2003 2147 2163
39. P. Hohenstein Tumour suppressor genes-one hit can be enough PLoS Biol. 2 2004 40
40. H. Lee, D.S. Park, B. Razani, R.G. Russell, R.G. Pestell, and M.P. Lisanti Caveolin-1 mutations (P132L and null) and the pathogenesis of breast cancer: caveolin-1 (P132L) behaves in a dominant-negative manner and caveolin-1 (-/-) null mice show mammary epithelial cell hyperplasia Am. J. Pathol. 161 2002 1357 1369
41. C. Kuang, and Y. Chen Tumor-derived C-terminal mutations of Smad4 with decreased DNA binding activity and enhanced intramolecular interaction Oncogene 23 2004 1021 1029
42. M. Miyaki, T. Iijima, M. Konishi, K. Sakai, A. Ishii, M. Yasuno, T. Hishima, M. Koike, N. Shitara, T. Iwama, J. Utsunomiya, T. Kuroki, and T. Mori Higher frequency of Smad4 gene mutation in human colorectal cancer with distant metastasis Oncogene 18 1999 3098 3103
43. S. Venkatachalam, Y.P. Shi, S.N. Jones, H. Vogel, A. Bradley, D. Pinkel, and L.A. Donehower Retention of wild-type p53 in tumors from p53 heterozygous mice: reduction of p53 dosage can promote cancer formation EMBO J. 17 1998 4657 4667
44. M.G. van Oijen, and P.J. Slootweg Gain-of-function mutations in the tumor suppressor gene p53 Clin. Cancer Res. 6 2000 2138 2145
45. A.I. Zaika, N. Slade, S.H. Erster, C. Sansome, T.W. Joseph, M. Pearl, E. Chalas, and U.M. Moll DeltaNp73, a dominant-negative inhibitor of wild-type p53 and TAp73, is up-regulated in human tumors J. Exp. Med. 196 2002 765 780